BioMarin's drug shows significant growth gains in children in late-stage trial

BioMarin Pharmaceutical said on Wednesday its treatment for a rare condition that leads to ​short stature helped boost growth in ‌children, meeting the main goal of a late-stage study and sending shares up nearly 5% in extended ​trading.